HomeNON PROFIT

Parkinson’s Foundation Invests $3.4 Million in Research Grants

The Parkinson’s Foundation today announced a $3.4 million investment across 34 research grants to advance promising Parkinson’s disease (PD) research. Grants support Parkinson’s research across a variety of disciplines for scientists who are actively studying various aspects of Parkinson’s with the hope of making life better for people with the disease and ultimately, leading to a cure.

“The Parkinson’s Foundation continues to provide these annual grant opportunities especially during the COVID-19 pandemic to ensure that PD research can successfully move forward,” said John L. Lehr, President and Chief Executive Officer of the Parkinson’s Foundation. “These research grants are critical to driving better patient outcomes and ensuring a better future for people with Parkinson’s disease.”

Parkinson’s Foundation research grants fund a diverse array of research studies that provide pre and postdoctoral researchers with training opportunities and established scientists and clinicians with the support to test innovative ideas that can lead to impactful research findings in the Parkinson’s field.

“With the support of the Parkinson’s Foundation, we hope to better understand how the nervous system functions as it relates to people with advanced Parkinson’s disease experience freezing gait, an inability to move their feet, during demanding or particularly stressful situations,” said Kevin Wilkins, Ph.D., a postdoctoral grant recipient. “We hope to develop ways to identify those at risk of developing cognitive and walking impairments as their disease progresses and provide the key to better therapies.”

This year the Foundation invested $450,000 in Impact Award programs. This award supports high-risk, high-reward projects that discover more about the biology of Parkinson’s and new treatments to people with Parkinson’s. Impact Award recipients received a maximum of $150,000 for approximately one year.

“These research grants allow us to better understand Parkinson’s disease and move the needle forward for better care and therapies for people with PD,” said James Beck, PhD, Chief Scientific Officer of the Parkinson’s Foundation. “We are thrilled to support these highly-promising grant recipients as they advance research towards a cure.”

Parkinson’s Foundation research investments are selected through a competitive application process and peer-reviewed by a panel that includes scientific experts and Foundation-trained research advocates. Since 1957, the Foundation has invested more than $365 million in Parkinson’s research and clinical care.

Research award categories include independent investigator awards, fellowships and early career awards, collaborative fellowships awards and Parkinson’s Foundation Research Centers awards. For more information about Parkinson’s Foundation research grants, visit here.

SourceParkinson's Foundation
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society 2023 Annual Meeting

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."

Research Team at UNC Validates PixCell Medical’s HemoScreen as Game-Changer for Clozapine Monitoring in Psychiatry

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).

Inspira Technologies Collaborates with Ennocure for development of a Proprietary Bio-Electronic Treatment to Prevent Associated Bloodstream Infections in ICU Patients

Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

Medical Device News Magazine

Editorial Contact: mdnewsmagazine@infomeddnews.com

Medical Device News Magazine can help promote your medical devices, technologies, products or services. Advertising Contact: advmdn@infomeddnews.com

Telephone

© Copyright 2022 Medical Device News Magazine, is a division of PTM Healthcare Marketing, Inc

By using this website you agree to accept Medical Device News Magazine Privacy Policy